Literature DB >> 6931261

Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model.

D S Alberts, Y M Peng, H S Chen, T E Moon, T C Cetas, J D Hoeschele.   

Abstract

A small-animal model was developed as a guide to whole-body hyperthermia in cancer patiens. Anesthetized DBA/2 mice were secured to a platform, and their hindlimbs were immersed in a 42.3 degrees C water bath for 30-60 minutes. Hindlimb hyperthermia reulted in steady-state rectal and femoral bone marrow and muscle temperatures of 42 degrees C and upper extremity muscle and esophagus temperatures of 41 degrees C. With this hyper thermia technique, the mouse spleen colony assay could be used to quantitate the lethality of hyperthermia and/or cis-dichloro-diammineplatinum(II) (cis-platinum) on clonogenic bone marrow and leukemia cells. Hyperthermia prior to cis-platinum administration increased cis-platinum inhibition of leukemia colony formation as much as 2 logs; however, antileukemia synergism ws greatest when cis-platinum administration immediately preceded hyperthermia and no evidence existd of synergism against normal bone marrow colonies. Correlative in vivo drug uptake studies showed a marked increase in leukemia cell uptake of 195mPt-cis-platinum at elevated temperatures, which suggested a potential mechanism for the apparent antileukemia synergism of cis-platinum and heat.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6931261

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

Authors:  Chelsea D Landon; Ji-Young Park; David Needham; Mark W Dewhirst
Journal:  Open Nanomed J       Date:  2011-01-01

2.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

3.  Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells.

Authors:  S Ohno; Z H Siddik; Y Kido; L A Zwelling; J M Bull
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Radiation-induced esophageal carcinoma responded well to hyperthermic chemotherapy--a case report.

Authors:  H Kai; Y Yoshida; H Matsufuji; K Sugimachi; K Inokuchi
Journal:  Jpn J Surg       Date:  1985-05

5.  Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.

Authors:  H Gerad; M J Egorin; M Whitacre; D A Van Echo; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Potentiation of platinum analogue cytotoxicity by hyperthermia.

Authors:  M J Xu; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role?

Authors:  Michelle M Boisen; Scott D Richard; Matthew P Holtzman; Robert P Edwards; Joseph L Kelley; Mohammad Haroon Choudry; David Bartlett; Marilyn Huang
Journal:  J Gastrointest Oncol       Date:  2016-02

8.  Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.

Authors:  I Takahashi; Y Maehara; H Kusumoto; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line.

Authors:  E Kimura; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.

Authors:  C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2009-01-14       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.